| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500656 | Farmacia Hospitalaria | 2006 | 7 Pages |
Abstract
Selecting an aromatase inhibitor is a valid option in neoadjuvancy, even if such selection would represent a very high cost for metastatic cancer.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
A. Ballester Viéitez, F. Ferriols Lisart, J. Magraner Gil,